CompletedNot Applicable

Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring

United States10 participantsStarted 2020-02-13

Plain-language summary

To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturizer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * male or females * age 18 and older * with evidence of grade II-III acne scars on the face (mild to moderate) as determined by the Goodman \& Baron qualitative global acne scar grading system Exclusion Criteria: * treatment to face with any energy device within 6 months * tanning within 7 days * dermabrasion or chemical peel within 3 months * current use of systemic retinoids * keloidal scaring in the treatment area * use of systemic steroids within 6 months * use of topical products with retinoid, alpha-hydroxyacid, salicylic acid, vitamin C or E within 14 days

What they're measuring

Mean Change From Baseline in Erythema

Timeframe: baseline to day 34

Mean Change From Baseline in Erythema

Timeframe: baseline to day 4

Trial details

NCT IDNCT04606134

SponsorUniversity of Rochester

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-06-18

Results submitted2022-07-19

View on ClinicalTrials.gov More Acne Scars - Mixed Atrophic and Hypertrophic trials